Background

Despite major progress in HIV prevention, substantial gaps remain in PrEP awareness, uptake, and persistence. Globally, only a fraction of individuals who could benefit from PrEP are currently using it, and in the United States, access remains uneven across populations disproportionately affected by HIV, including Black and Latino men who have sex with men, transgender women, women, and communities in the Southern United States. Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) represents an important advancement in prevention science by expanding choice beyond daily oral PrEP and helping address barriers related to pill burden, stigma, and adherence.

Program

Long-Acting Injectable HIV PrEP is an IAPAC Learning Academy educational activity designed to strengthen clinicians’ knowledge, confidence, and clinical judgment in the implementation of evidence-based, person-centered, and equitable approaches to LAI-PrEP. This module reviews the pharmacology and administration of current long-acting PrEP agents, summarizes key efficacy and safety data, and explores practical strategies for integrating LAI-PrEP into clinical care through shared decision-making and equity-focused implementation.

Target Audience

This activity has been designed to meet the educational needs of clinicians and other healthcare professionals involved in HIV prevention, care, and treatment, including physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other members of the interprofessional care team. It is particularly relevant for providers seeking to expand HIV prevention options and improve equitable access to person-centered PrEP services.

Learning Objectives

Upon completion of this activity, learners should be able to:

  1. Describe the pharmacology and administration of current LAI-PrEP agents
  2. Summarize efficacy and safety data from pivotal studies of long-acting injectable PrEP
  3. Implement LAI-PrEP through shared decision-making that respects patient choice, autonomy, and equitable access to care

Course Content

This module reviews the evolving role of long-acting injectable PrEP in HIV prevention and includes content on:

  • The epidemiology of HIV and the unmet need for expanded PrEP access
  • Mechanisms of action of cabotegravir and lenacapavir
  • Key clinical evidence from HPTN 083, HPTN 084, and PURPOSE studies
  • Baseline testing, follow-up monitoring, and implementation considerations for LAI-PrEP
  • Common implementation challenges and innovative models of care, including pharmacy-based delivery and community-centered approaches
  • Case studies illustrating adherence, stigma, and patient-centered decision-making in clinical practice

Contact

For questions about this educational activity, please contact jhess@iapac.org.

Course Content

Modules Status